Clinical trial · Interventional
The Effect of Ketamine on Immune Function and Prognosis in Patients Undergoing Colorectal Cancer Resection
NCT03273231CI-TRIAL-00036577unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Systemic inflammation caused by surgery may aggravate immunosuppression in immunocompromised cancer patients. The natural killer (NK) cell is a critical part of anti-tumor immunity. ketamine, a N-methyl-D-asparate receptor antangonist, has anti-inflammatory activity and opioid-sparing effect. This study investigate the effect of intraopertaive ketamine administration on immune function in patients undergoing laparoscopic colorectal cancer resection.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ketamine | Drug | — | UNRESOLVED |
| Saline | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- ketamine group
- description
- Ketamine is administered intravenously with a loading dose of 0.25 mg/kg at 5 minutes before surgery, followed by an infusion rate of 0.05 mg/kg/h to the end of surgery.
- interventionNames
- Drug: Ketamine
- type
- PLACEBO_COMPARATOR
- label
- control group
- description
- 0.9% saline solution
- interventionNames
- Drug: Saline
Primary outcomes (4)
- measure
- natural killer cell cytotoxicity
- timeFrame
- Baseline
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * patient between 20 and 80 of age with ASA physical status Ⅰ-Ⅲ * patient scheduled for laparoscopic colorectal cancer resection Exclusion Criteria: * ASA physical status Ⅳ * severe hepatorenal disease * heart failure * infection * increased intracranial pressure, seizure * preoperative chemotherapy * immune or endocrine disease * metastasis to other organ * problem with communication * pregnancy * body mass index \> 35 kg/m2
References
Publications (1)
- DERIVEDCho JS, Kim NY, Shim JK, Jun JH, Lee S, Kwak YL. The immunomodulatory effect of ketamine in colorectal cancer surgery: a randomized-controlled trial. Can J Anaesth. 2021 May;68(5):683-692. doi: 10.1007/s12630-021-01925-3. Epub 2021 Feb 2. PMID 33532995